A Targeted Bivalent Androgen Receptor Binding Compound for Prostate Cancer Therapy.

ABSTRACT: The androgen-directed treatment of prostate cancer (PCa) is fraught with the recurrent profile of failed treatment due to drug resistance and must be addressed if we are to provide an effective therapeutic option. The most singular difficulty in the treatment of PCa is the failure to respond to classical androgen withdrawal or androgen blockade therapy, which often develops as the malignancy incurs genetic alterations and gain-of-function somatic mutations in the androgen receptor (AR). Physical cellular damaging therapeutic agents, such as radiation or activatable heat-generating transducers would circumvent classical "anti-functional" biological resistance, but to become ultimately effective would require directed application modalities. To this end, we have developed a novel AR-directed

SUBMITTER: Chowdhury S 

PROVIDER: S-EPMC10355713 | biostudies-literature | 2019 Feb

REPOSITORIES: biostudies-literature